Published in Can J Cardiol on February 01, 2006
Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: a meta-analytic review. PLoS One (2012) 1.88
Characteristics, treatment and one-year outcomes of patients with acute coronary syndrome in a tertiary hospital in India. Indian Heart J (2013) 0.75
Enduring somatic threat perceptions and post-traumatic stress disorder symptoms in survivors of cardiac events. J Health Psychol (2017) 0.75
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
International differences in evolution of early discharge after acute myocardial infarction. Lancet (2004) 2.47
Regionalization of care for acute ischemic heart disease: a call for specialized centers. Circulation (2003) 2.35
A prospective study of complications of pulmonary artery catheterizations in 500 consecutive patients. Chest (1983) 1.56
A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol (2002) 1.54
Need for centers to care for patients with acute coronary syndromes. Circulation (2003) 1.30
A community-wide assessment of the use of pulmonary artery catheters in patients with acute myocardial infarction. Chest (1987) 1.11
Declining length of hospital stay for acute myocardial infarction and postdischarge outcomes: a community-wide perspective. Arch Intern Med (2004) 1.00
Population rates of invasive cardiac procedures in British Columbia, 1995 to 2001. Can J Cardiol (2004) 0.89
Progress in the treatment of acute coronary syndromes: a 50-year perspective (1950-2000). Circulation (2000) 0.87
Prolonged hospital stay after acute myocardial infarction: assessing the evidence. Lancet (2004) 0.81
Risk stratification, management and outcomes of patients with non-ST elevation acute coronary syndrome: a Canadian teaching hospital perspective. Can J Cardiol (2003) 0.81
Editor's commentary: centers of excellence. Circulation (2003) 0.80
Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med (2015) 6.68
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med (2015) 5.36
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation (2006) 4.69
Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation (2008) 4.43
Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol (2011) 4.12
Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 3.69
Mapping and ablation of idiopathic ventricular fibrillation. Circulation (2002) 3.69
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA (2007) 3.12
Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. Circulation (2013) 2.90
Technique and results of linear ablation at the mitral isthmus. Circulation (2004) 2.74
Comparison of gas exchange data using the Aquatrainer system and the facemask with Cosmed K4b2 during exercise in healthy subjects. Eur J Appl Physiol (2010) 2.73
The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry (2004) 2.62
Job strain and risk of acute recurrent coronary heart disease events. JAMA (2007) 2.61
Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation (2007) 2.59
Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA (2006) 2.38
Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex ≥120 milliseconds. Circulation (2011) 2.36
Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol (2009) 2.23
Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries. J Am Coll Cardiol (2005) 2.14
Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J (2013) 2.14
Prevalence of pulmonary vein disconnection after anatomical ablation for atrial fibrillation: consequences of wide atrial encircling of the pulmonary veins. Eur Heart J (2005) 2.14
Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail (2012) 2.13
Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med (2006) 2.13
"Dormant" pulmonary vein conduction revealed by adenosine after ostial radiofrequency catheter ablation. J Cardiovasc Electrophysiol (2004) 2.00
Current percutaneous treatment strategies for saphenous vein graft disease. Catheter Cardiovasc Interv (2013) 1.96
Efficacy and safety of cryoballoon ablation for atrial fibrillation: a systematic review of published studies. Heart Rhythm (2011) 1.93
Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation (2007) 1.88
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up. Heart Rhythm (2008) 1.77
Percutaneous transvenous mitral annuloplasty: initial human experience with a novel coronary sinus implant device. Circ Cardiovasc Interv (2009) 1.77
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol (2004) 1.76
Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: a report from the Canadian Heart Rhythm Society Device Advisory Committee. Heart Rhythm (2008) 1.71
Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol (2013) 1.70
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 1.69
Improved outcome following restoration of sinus rhythm prior to catheter ablation of persistent atrial fibrillation: a comparative multicenter study. Heart Rhythm (2012) 1.67
Dissociated pulmonary vein arrhythmia: incidence and characteristics. J Cardiovasc Electrophysiol (2003) 1.63
Absence of association between infectious agents and endothelial function in healthy young men. Circulation (2003) 1.60
Incidence and significance of early recurrences of atrial fibrillation after cryoballoon ablation: insights from the multicenter Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) Trial. Circ Arrhythm Electrophysiol (2014) 1.59
Pulmonary vein isolation using a second-generation cryoballoon catheter: a randomized comparison of ablation duration and method of deflation. J Cardiovasc Electrophysiol (2013) 1.57
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv (2009) 1.56
Complications associated with revision of Sprint Fidelis leads: report from the Canadian Heart Rhythm Society Device Advisory Committee. Circulation (2010) 1.55
Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol (2010) 1.55
Percutaneous mitral valve annuloplasty for ischemic mitral regurgitation: first in man experience with a temporary implant. Catheter Cardiovasc Interv (2007) 1.53
Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol (2005) 1.53
Quantitative hyperemic reactivity in opposed limbs during myocardial perfusion imaging: a new marker of coronary artery disease. J Am Coll Cardiol (2004) 1.53
Efficacy and safety of atrial fibrillation ablation with phased radiofrequency energy and multielectrode catheters. Heart Rhythm (2011) 1.51
Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. Cardiovasc Res (2008) 1.51
Extraction of transvenous leads in the operating room versus electrophysiology laboratory: a comparative study. Heart Rhythm (2011) 1.50
Utilization of a national network for rapid response to the Medtronic Fidelis lead advisory: the Canadian Heart Rhythm Society Device Advisory Committee. Heart Rhythm (2009) 1.48
Percutaneous closure of secundum atrial septal defect in adults a single center experience with the amplatzer septal occluder. J Invasive Cardiol (2003) 1.48
Shocking truths about implantable cardioverter defibrillator monitoring zones. Pacing Clin Electrophysiol (2007) 1.48
Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention. J Interv Cardiol (2009) 1.47
Comparison of left ventricular contraction homogeneity index using SPECT gated blood pool imaging and planar phase analysis. J Nucl Cardiol (2007) 1.47
Improvement in exercise capacity in asymptomatic and mildly symptomatic adults after atrial septal defect percutaneous closure. Circulation (2002) 1.46
Histopathology of cryoballoon ablation-induced phrenic nerve injury. J Cardiovasc Electrophysiol (2013) 1.45
Importance of collateral circulation in coronary heart disease. Eur Heart J (2007) 1.45
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol (2009) 1.45
Differential effectiveness of pharmacological strategies to reveal dormant pulmonary vein conduction: a clinical-experimental correlation. Heart Rhythm (2011) 1.45
Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation (2004) 1.45
The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol (2012) 1.44
Incidence and significance of early recurrences associated with different ablation strategies for AF: a STAR-AF substudy. J Cardiovasc Electrophysiol (2012) 1.44
Antimicrobial peptides: natural effectors of the innate immune system. Semin Immunopathol (2007) 1.43
Effect of interval training on cognitive functioning and cerebral oxygenation in obese patients: a pilot study. J Rehabil Med (2014) 1.42
Two-year angiographic follow-up of intracoronary Sr90 therapy for restenosis prevention after balloon angioplasty. Circulation (2002) 1.42
Anodal right ventricular capture during left ventricular stimulation in CRT-implantable cardioverter defibrillators. Pacing Clin Electrophysiol (2005) 1.42
High energy excimer laser to treat coronary in-stent restenosis in an underexpanded stent. Catheter Cardiovasc Interv (2008) 1.41
Incidence of stent under-deployment as a cause of in-stent restenosis in long stents. Int J Cardiovasc Imaging (2004) 1.41
Feasibility and applicability of computer-assisted myocardial blush quantification after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Catheter Cardiovasc Interv (2010) 1.40
Enlargement of catheter ablation lesions in infant hearts with cryothermal versus radiofrequency energy: an animal study. Circ Arrhythm Electrophysiol (2011) 1.40
Transesophageal echocardiography for the prevention of embolic complications after catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol (2009) 1.40
A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction. Am Heart J (2003) 1.40
Anticoagulation management pre- and post atrial fibrillation ablation: a survey of canadian centres. Can J Cardiol (2012) 1.39
Lower incidence of thrombus formation with cryoenergy versus radiofrequency catheter ablation. Circulation (2003) 1.38
Differential 1-year clinical outcomes for ST-segment elevation myocardial infarction related to stent thrombosis or saphenous vein graft thrombosis. Catheter Cardiovasc Interv (2013) 1.38
VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther (2009) 1.37
Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation. Circulation (2002) 1.34
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med (2013) 1.32
Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation (2003) 1.32
Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation (2006) 1.31